Vimarsana
Biggest News Aggregation in the World

Page 2 - Gerry Brunk News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gerry Brunk. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gerry Brunk Today - Breaking & Trending Today

GenEp, Inc.: GenEp Raises $1.45 Million Seed Financing - Vimarsana News

GenEp, Inc.: GenEp Raises $1.45 Million Seed Financing

Financing will support development of first-in-class CNS-selective sodium channel modulatorsCHARLOTTESVILLE, VA / ACCESSWIRE / October 26, 2021 / GenEp, Inc., a biotechnology company developing therapies

Cyrano Therapeutics Raises $12.8 Million to Complete Phase 2 Trial of CYR-064 for the Restoration of - Vimarsana News

Cyrano Therapeutics Raises $12.8 Million to Complete Phase 2 Trial of CYR-064 for the Restoration of

Search jobs 10-Dec-2020 Cyrano Therapeutics Raises $12.8 Million to Complete Phase 2 Trial of CYR-064 for the Restoration of Chronic Smell and Flavor Loss WASHINGTON, Dec. 10, 2020 /PRNewswire/ -- Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy for smell and flavor restoration, has raised $12.8 million in a Series A financing led by Remiges Ventures and Lumira Ventures, with the participation of additional investors. The funds will be used to complete a Phase 2 clinical trial of the company...

Cyrano Therapeutics Raises $12.8 Million to Complete Phase 2 Trial of CYR-064 for the Restoration of Chronic Smell and Flavor Loss - Vimarsana News

Cyrano Therapeutics Raises $12.8 Million to Complete Phase 2 Trial of CYR-064 for the Restoration of Chronic Smell and Flavor Loss

Share this article Share this article WASHINGTON, Dec. 10, 2020 /PRNewswire/ -- Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy for smell and flavor restoration, has raised $12.8 million in a Series A financing led by Remiges Ventures and Lumira Ventures, with the participation of additional investors. The funds will be used to complete a Phase 2 clinical trial of the company's lead product, CYR-064, in the U.S. and Europe.  As part of the financing, Taka Koda of Remiges Ventures and Gerry Brunk of Lumira Ventures have joined the com...